Enterprise Value
2.608M
Cash
28.9M
Avg Qtr Burn
-6.055M
Short % of Float
0.73%
Insider Ownership
11.83%
Institutional Own.
9.78%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Allocetra (Immunotherapy) Details Organ failure, Treatment of organ failure associated with Sepsis | Phase 2b Data readout | |
Allocetra (Immunotherapy) Details Osteoarthritis | Phase 1/2 Data readout | |
Allocetra (Immunotherapy) +/_ anti-PD1 checkpoint inhibitors Details Solid tumor/s, Cancer | Failed Discontinued | |
Allocetra (Immunotherapy) Details Bone marrow transplantation, Prevention of post-bone marrow transplantations complications | Failed Discontinued | |
Tovinontrine (IMR-687) Details Beta thalessemia, Genetic disorder | Failed Discontinued | |
Tovinontrine (IMR-687) Details Sickle cell disease, Genetic disorder, Blood disorder | Failed Discontinued | |
Allocetra (Immunotherapy) + Chemotherapy Details Solid tumor/s, Cancer | Failed Discontinued | |
Allocetra (Immunotherapy) Details COVID-19, Non-alcoholic steatohepatitis , Liver disease | Failed Discontinued |